145 related articles for article (PubMed ID: 32238495)
1. Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment.
Jadvar H; Ballas LK; Choyke PL; Fanti S; Gulley JL; Herrmann K; Hope TA; Klitzke AK; Oldan JD; Pomper MG; Rowe SP; Subramaniam RM; Taneja SS; Vargas HA; Ahuja S
J Nucl Med; 2020 Apr; 61(4):552-562. PubMed ID: 32238495
[No Abstract] [Full Text] [Related]
2. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
Tan N; Bavadian N; Calais J; Oyoyo U; Kim J; Turkbey IB; Mena E; Davenport MS
J Urol; 2019 Aug; 202(2):231-240. PubMed ID: 30829130
[TBL] [Abstract][Full Text] [Related]
3. The timing of molecular imaging in prostate cancer.
Morris MJ
Clin Adv Hematol Oncol; 2018 Mar; 16(3):195-197. PubMed ID: 29742075
[No Abstract] [Full Text] [Related]
4. Imaging of local recurrence in prostate cancer.
McCammack KC; Raman SS; Margolis DJ
Future Oncol; 2016 Nov; 12(21):2401-2415. PubMed ID: 27306275
[TBL] [Abstract][Full Text] [Related]
5. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
6. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
8. ACR Appropriateness Criteria® posttreatment follow-up of prostate cancer.
Casalino DD; Remer EM; Arellano RS; Bishoff JT; Coursey CA; Dighe M; Eggli DF; Fulgham P; Israel GM; Lazarus E; Leyendecker JR; Nikolaidis P; Papanicolaou N; Prasad S; Ramchandani P; Sheth S; Vikram R
J Am Coll Radiol; 2011 Dec; 8(12):863-71. PubMed ID: 22137005
[TBL] [Abstract][Full Text] [Related]
9. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Hope TA; Aggarwal RR; Westphalen AC; Cooperberg MR; Greene KL
Future Oncol; 2016 Nov; 12(21):2393-2396. PubMed ID: 27453303
[No Abstract] [Full Text] [Related]
10.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
11. Patient-Friendly Summary of the ACR Appropriateness Criteria: Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.
Andrews DB; Lalani T
J Am Coll Radiol; 2019 Jan; 16(1):e1. PubMed ID: 30611386
[No Abstract] [Full Text] [Related]
12. Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.
Duvnjak P; Schulman AA; Holtz JN; Huang J; Polascik TJ; Gupta RT
Urol Clin North Am; 2018 Aug; 45(3):455-466. PubMed ID: 30031465
[TBL] [Abstract][Full Text] [Related]
13. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
14. Primary staging of prostate cancer.
Jager GJ; Barentz JO; Ruijter ET; de la Rosette JJ; Oosterhof GO
Eur Radiol; 1996; 6(2):134-9. PubMed ID: 8797969
[TBL] [Abstract][Full Text] [Related]
15. Is There Use for FDG-PET in Prostate Cancer?
Jadvar H
Semin Nucl Med; 2016 Nov; 46(6):502-506. PubMed ID: 27825430
[TBL] [Abstract][Full Text] [Related]
16. Prospective head-to-head comparison of
Eiber M; Rauscher I; Souvatzoglou M; Maurer T; Schwaiger M; Holzapfel K; Beer AJ
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2179-2188. PubMed ID: 28803358
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment staging of clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
Amis ES; Bigongiari LR; Bluth EI; Bush WH; Choyke PL; Fritzsche P; Holder L; Newhouse JH; Sandler CM; Segal AJ; Resnick MI; Rutsky EA
Radiology; 2000 Jun; 215 Suppl():703-8. PubMed ID: 11037488
[No Abstract] [Full Text] [Related]
18. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
Gorin MA; Rowe SP; Denmeade SR
PET Clin; 2017 Apr; 12(2):185-192. PubMed ID: 28267452
[TBL] [Abstract][Full Text] [Related]
19. The Impact of
Roach PJ; Francis R; Emmett L; Hsiao E; Kneebone A; Hruby G; Eade T; Nguyen QA; Thompson BD; Cusick T; McCarthy M; Tang C; Ho B; Stricker PD; Scott AM
J Nucl Med; 2018 Jan; 59(1):82-88. PubMed ID: 28646014
[No Abstract] [Full Text] [Related]
20. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
